Thesis (Ph. D.)--University of Missouri-Columbia, 1996. / Typescript. Vita. Includes bibliographical references (leaves 145-158). Also available on the Internet.

Made available in DSpace on 2014-06-11T19:33:29Z (GMT). No. of bitstreams: 0 Previous issue date: 2010-08-19Bitstream added on 2014-06-13T19:04:27Z : No. of bitstreams: 1 moreira_tms_dr_arafcf.pdf: 1452278 bytes, checksum: 746ea7e0008db7d637ec414f27c288bf (MD5) / Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP) / O gênero Candida é causa frequente de infecção da mucosa oral e vaginal, sendo motivo de preocupação na área de saúde devido à reincidência das infecções, crescimento de infecções sistêmicas, resistência de diversas cepas e toxicidade dos antifúngicos. Plantas medicinais são usadas popularmente no tratamento de candidíases e por este motivo, busca-se, além de avaliar a composição fitoquímica do óleo de Melaleuca alternifolia (Myrtaceae) e do extrato de Plinia cauliflora (Myrtaceae), verificar o mecanismo de ação destas amostras sobre diferentes espécies de Candida. A constituição do óleo essencial de M. alternifolia está descrita na literatura e por cromatografia gasosa identificou-se a presença de substâncias importantes da sua composição na amostra utilizada. Foi traçado o perfil cromatográfico do extrato das folhas e das frações de P. cauliflora para conhecer sua constituição. Foram isoladas duas miricetinas e duas quercetinas glicosiladas e o elagitanino casuarinina. Na avaliação da atividade anti-Candida, o óleo essencial apresentou-se fungicida, com concentração citotóxica de 50% na mesma faixa. Entre as amostras avaliadas de P. cauliflora, o extrato, a fração butanólica e a fração enriquecida com o derivado elágico apresentaram a melhor atividade, foram fungistáticas e a concentração citotóxica foi maior que a concentração ativa. O óleo essencial mostrou-se inibidor da formação de hifas, reduziu a quantidade de ergosterol, sem se ligar a este composto e promoveu alterações significativas principalmente na parede celular da forma filamentosa. Por outro lado, as frações mais ativas de P. cauliflora inibiram o desenvolvimento de hifas, mas estimularam a síntese de ergosterol e indicaram ter mais de um alvo de ação, ligando-se ao ergosterol e agindo externamente por modificação do arranjo da parede celular das espécies... / Candida genus is often the reason of oral and vaginal mucosal infections and it is cause of concern in the health area due to the relapsing of infections, rising in the number of systemic infections, resistance of several strains and high toxicity of synthetized antifungal agents. Medicinal plants have been used in the treatment of candidiasis, and this is the reason to evaluate the phytochemical composition of essential oil from Melaleuca alternifolia (Myrtaceae) and extract of Plinia cauliflora (Myrtaceae) in order to verify their mechanism of action against different species of Candida. The constitution of the essential oil is already described in the literature and it was possible to confirm the compounds by gas chromatography in the sample utilized. It was studied the fingerprint of the extract of P. cauliflora leaves and fraction applying chromatographic techniques. It was isolated two glucosilated myricetin and quercetin and the ellagitannin casuarinin. The essential oil showed fungicidal activity against Candida with 50% of cytotoxicity in the same concentration rate of the activity. Among samples of P. cauliflora, extract, butanolic fraction and the riched fraction with the ellagic acid derivate showed the better activity but it was fungistatic. The cytotoxic concentration was higher than the concentration of action. The essential oil showed to inhibit hyphae formation, to reduced the amount of ergosterol without binding to it and there were significative changes mainly in the hyphal cell wall. The more active fractions of P. cauliflora inhibited hiphae development, stimulated ergosterol synthesis and indicated to have more than just one target since they bound directly to ergosterol and showed to act externally by changing cell wall assemble without changes in the composition. Thus, the fungicidal activity of M. alternifolia essential oil is mainly due... (Complete abstract click electronic access below)

GEMMOTHERAPY AND ITS USE IN PRACTISE Student: Škodová Adriana Tutor: PharmDr. Jitka Pokladníková, Ph.D. Department of Social and Clinical Pharmacy, Faculty of Pharmacy in Hradec Králové, Charles University in Prague, Czech Republic Introduction: Gemmotherapy or budding medicine is an herbal healing method, whose roots go back to the Middle Ages and folk healing. It uses germ-shaped parts of plants (especially buds) for the production of liqueur glycerin macerates, which are proven to contain larger quantities of some important substances with healing properties than adult parts of plants. Objectives: The aim of this work was to summarize basic information about gemmotherapy from available literature; to summarize the description of the traditional use of selected plants and gemmotherapeutics prepared therefrom; to provide a summary of studies based on evidence-based literature, especially with regard to content and confirmatory medicinal properties, adverse effects, drug interactions and contraindications. Methods: General information about gemmotherapy was mainly drawn from books available in the Czech language. Data collection took place from October 2016 to August 2017, and researches based on literature were mainly based on the electronic databases PubMed, Web of Science, Wiley Online Library,...

Kalanchoe pinnata (Lam.) Pers. (Crassulaceae) é uma espécie muito empregada na medicina tradicional no Brasil e em outras partes do mundo, especialmente Índia, países da África e China. É indicada popularmente para diversos fins incluindo o tratamento de úlceras gástricas. A análise fitoquímica revelou a presença de vários constituintes, em especial os flavonoides. O tratamento de úlcera gástrica convencional apresenta diversos efeitos colaterais e, na maioria das vezes, não evita a recidiva da lesão. Dessa maneira, é interessante encontrar uma terapêutica mais segura e efetiva. Com o objetivo de avaliar a segurança, foi realizado ensaio de citotoxicidade do extrato bruto, in vitro, com valor de IC50 igual a 0,926 mg/mL, sendo possível predizer um valor de LD50 (1341,46 mg/kg). Já em relação ao ensaio de citotoxicidade, in vitro, da fração acetato de etila não foi encontrado um valor de IC50. Resultados de fototoxicidade, in vitro, mostraram que o extrato bruto e fração acetato de etila de K. pinnata não possuem potencial fototóxico. A contagem microbiana na droga vegetal para bactérias aeróbias/mesófilas foi de 6,9 x 104 UFC/g e a contagem de bolores e leveduras foi de 2,4 x 103 UFC/g, ambos valores dentro do limite estabelecido pela OMS. Análise de endotoxinas também foi realizada para o extrato bruto (<4,0.105 UE/kg) e fração acetato de etila (<2,7.105 EU/kg) de K. pinnata. Referente à fitoquímica, diversos flavonoides foram identificados no extrato bruto e fração acetato de etila de K. pinnata. Paralelamente ao estudo fitoquímico foi verificado que a atividade gastroprotetora do extrato bruto envolve a ação das prostaglandinas e grupamentos sulfidrila. Já o mecanismo de gastroproteção da fração acetato de etila é dependente de prostaglandinas e óxido nítrico. A atividade cicatrizante do extrato bruto de K. pinnata também foi avaliada. De acordo com os resultados macroscópicos, as doses de 200mg/kg e 400 mg/kg reduziram a área de lesão, com uma taxa de 33% e 39%, respectivamente, após 7 dias de tratamento (p<0,05). Análise histológica dos grupos tratados com o extrato bruto (200 e 400 mg/kg) indicou melhor recuperação da lesão, verificada pela regeneração da mucosa gástrica e pelo restabelecimento da arquitetura glandular. As enzimas antioxidantes (catalase, superóxido dismutase e glutationa peroxidase) e a expressão de VEGF foram avaliadas no mecanismo de cicatrização de úlceras gástricas. Os resultados mostraram que a atividade antiulcerogênica foi mediada pela ação antioxidante da enzima SOD. Não foi evidenciado in vivo o aumento da expressão de VEGF e nem o sequestro do radical peroxil nos animais tratados com o extrato bruto. Os resultados dos ensaios in vitro (ORAC) mostraram uma maior capacidade de sequestro de radicais peroxil da fração acetato de etila (1192,35 ± 112,61 &#181;mol equivalente de Trolox/g de amostra seca) quando comparado com o extrato bruto (431,32 ± 7,17 &#181;mol equivalente de Trolox/g de amostra seca). A atividade anti Helicobacter pylori também foi avaliada, no entanto, o extrato bruto não apresentou atividade anti H.pylori. Ademais, o extrato bruto demonstrou um potencial anti-inflamatório, pois foi observada uma redução nos níveis de TNF-&#945; e L-selectina, após o tratamento em neutrófilos estimulados com LPS. Analisando os resultados sugere-se que K. pinnata possui um potencial terapêutico no combate de úlceras gástricas e possivelmente, anti-inflamatório, sendo que os flavonoides podem estar relacionados com o efeito biológico observado. / Kalanchoe pinnata (Lam.) Pers. (Crassulaceae) is a commonly used species in traditional medicine in Brazil and in other parts of the world, especially India, Africa and China, for the treatment of various diseases, including gastric ulcers. Phytochemical analysis revealed the presence of several constituents in this plant, especially flavonoids. The available pharmaceutical products to treat peptic ulcer have several side effects and, in most cases, do not prevent recurrence of the gastric lesions. Therefore, it is important to find a safer and more effective therapy. In order to evaluate safety, the in vitro cytotoxicity assay of crude extract from K. pinnata was performed. The IC50 value was 0,926 mg/mL corresponding to LD50 value (1341, 46 mg/kg). It was not determined IC50 value in vitro cytotoxicity assay for ethyl acetate fraction from K. pinnata. Neither the crude extract nor ethyl acetate fraction from K. pinnata showed phototoxicity. Microbial counting was performed on the K. pinnata-based drug in order to investigate microbiological contamination. The microbial count for aerobic / mesophilic bacteria was 6.9 x 104 CFU/g, and yeast count was 2.4 x 103 CFU/g, both values in agreement with the limits established by WHO. Endotoxin analysis was also performed for the crude extract (<4,0.105 UE/kg) and for ethyl acetate fraction (<2,7.105 UE/kg) from K. pinnata. In the phytochemical analysis several flavonoids were identified in the crude extract and ethyl acetate fraction of K. pinnata. In parallel to the phytochemical study, it was verified that the gastroprotective activity of the crude extract of K. pinnata involved prostaglandins and sulfhydril compounds. On the other hand, the mechanism of gastroprotection of the ethyl acetate fraction of K. pinnata is dependent on prostaglandins and nitric oxide. The healing activity of the crude extract of K. pinnata was also evaluated. According to the macroscopic results the dose of 200 mg/kg and 400mg/kg reduced the injury area, with a rate of 33% and 39%, respectively, after 7 days of treatment (p <0.05). Histological analysis showed regeneration of the gastric mucosa and re-establishment of the glandular architecture in groups treated with the crude extract (200 and 400 mg/kg). Antioxidant enzymes (catalase, superoxide dismutase and glutathione peroxidase) and VEGF expression were evaluated in the mechanism of gastric ulcer healing. The results showed that the antiulcerogenic activity was mediated by SOD. It was not demonstrated an increase in VEGF expression and nor in the in vivo sequestration of the peroxyl radical in the animals treated with crude extract. The results of in vitro assay (ORAC) showed a greater sequestering of peroxyl radical to the ethyl acetate fraction (1192,35 ± 112,61 &#181;mol equivalent of Trolox/g of ethyl acetate fraction) when compared to the crude extract (431,32 ± 7,17 &#181;mol equivalent of Trolox/g of crude extract) of K. pinnata. The anti Helicobacter pylori activity was also evaluated; however, the crude extract did not show anti H. pylori activity. However, the crude extract of K. pinnata demonstrated an anti-inflammatory potential, because TNF-&#945; and L-selectin levels were reduced after treatment in LPS-stimulated neutrophils. The analysis of the results suggests that K. pinnata has a therapeutic potential against gastric ulcers and possible anti-inflammatory properties, and the flavonoids may be linked to the biological effect.

Submitted by Cássia Santos (cassia.bcufg@gmail.com) on 2016-08-12T11:00:29Z No. of bitstreams: 2 Dissertação - Maysa Paula da Costa - 2012.pdf: 1943875 bytes, checksum: b80f4f02efcb888e3b6b59c7d58f6bc8 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2016-08-12T14:06:08Z (GMT) No. of bitstreams: 2 Dissertação - Maysa Paula da Costa - 2012.pdf: 1943875 bytes, checksum: b80f4f02efcb888e3b6b59c7d58f6bc8 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) / Made available in DSpace on 2016-08-12T14:06:08Z (GMT). No. of bitstreams: 2 Dissertação - Maysa Paula da Costa - 2012.pdf: 1943875 bytes, checksum: b80f4f02efcb888e3b6b59c7d58f6bc8 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2016-02-29 / Coordenação de Aperfeiçoamento de Pessoal de Nível Superior - CAPES / Increases in antimicrobial resistance and the side effects of available antifungal drugs have increased the need to develop new and more effective antifungal agents. Among the compounds extracted from plants, flavonoids have been considered to be possible sources of new therapeutics for fungal, bacterial and viral infections. The antifungal mechanism of action and toxicity of fisetin, flavonoid with antifungal activity previously established for the Cryptococcus neoformans species complex and dermatophytes were determined. The action of this flavonoid was evaluated by quantitation of ergosterol, cell viability by flow cytometry and by changes in fungal morphology visualized by scanning electron microscopy. The fisetin toxicity was determined in vitro through the evaluation of hemolytic and myelotoxic potential and in vivo by acute oral toxicity. Hepatotoxicity of this flavonoid in hepatocellular carcinoma cell line (Hepg2) was performed by determination of mitochondrial viability using the MTT reduction method, evaluation of cellular and nuclear morphology by staining with May-Grunwald-Giemsa and Hoechst 33342 and analysis of viability and death cell by method of phosphatidylserine externalization. The obtained results have allowed to verify that the yeast subjected to the action of the fisetin showed a content ergosterol reduction, changes in cellular metabolism viewed in flow cytometry. Fungal cells treated with fisetin and observed by scanning electron microscopy showed in the analysis of yeast C. neoformans complex, retraction in the cell cytoplasm and in the dermatophytes there have been changes in hyphae and sharp reduction of conidia. The toxicological analysis of fisetin, observed a low potential hemolytic and an absence of damage on the granulocyte-macrophage progenitors cells. Animals treated with fisetin did not show behavioral changes, with liver and kidneys macroscopically normal. The cytotoxicity assessment observed on HepG2 cells in different concentrations of the compound showed cell viability with a range of 65.9% to 18.5% at concentrations from 3.12 to 400 μg/mL fisetin, suggesting that the action this flavonoid on the HepG2 cell line is concentration-dependent. Rare cellular and nuclear morphological changes, with few cells in apoptosis were observed in HepG2 cells in the presence of fisetin. In conclusion, although many cytotoxicity assays and mechanism of action must be made to introduce fisetin as a new drug, the present results show a favorable profile to conduct the study and development of this substance in the treatment of cryptococcosis and dermatophytosis. / O aumento na resistência aos antibióticos e os efeitos colaterais dos antifúngicos disponíveis têm aumentado a necessidade de desenvolver novos e mais eficazes agentes antifúngicos. Entre os compostos extraídos de plantas, os flavonóides são considerados como possíveis fontes de novos agentes terapêuticos para infecções fúngicas, bacterianas e virais. O mecanismo de ação antifúngica e a toxicidade de fisetina, flavonóide com atividade antifúngica previamente estabelecida para o complexo de espécies Cryptococcus neoformans e dermatófitos, foram determinados. A ação deste flavonóide foi avaliada pelo doseamento de ergosterol, pela viabilidade celular por citometria de fluxo e por alterações na morfologia fúngica visualizadas por microscopia eletrônica de varredura. A toxicidade de fisetina foi determinada in vitro através da avaliação do potencial hemolítico e mielotóxico e in vivo pela toxicidade oral aguda. A hepatotoxicidade deste flavonóide, em células da linhagem de carcinoma hepatocelular HepG2, foi realizada pela determinação da viabilidade mitocondrial usando o método de redução de MTT, avaliação da morfologia celular e nuclear por coloração com May-Grunwald-Giemsa e Hoechst 33342 e análise da viabilidade e morte celular pelo método de externalização da fosfatidilserina. Os resultados obtidos permitiram verificar que as leveduras submetidas à ação de fisetina apresentaram redução do conteúdo de ergosterol, alteração no metabolismo celular visualizadas na citometria de fluxo. As células fúngicas tratadas com fisetina e observadas por microscopia eletrônica de varredura apresentaram, na análise de leveduras do complexo C. neoformans, retração no citoplasma celular e nos dermatófitos verificaram-se modificações nas hifas e redução acentuada de conídios. Na análise toxicológica de fisetina, observou-se baixo potencial hemolítico e ausência de danos nas células progenitoras de granulócitos e macrófagos. Animais tratados com fisetina não apresentaram alterações de comportamento, com fígado e rins macroscopicamente normais. A avaliação de citotoxicidade verificada sobre células HepG2 em diferentes concentrações do composto mostrou viabilidade celular com uma variação de 65,9% a 18,5% em concentrações de 3,12 a 400 μg/mL de fisetina, sugerindo que a ação deste flavonóide sobre a linhagem celular HepG2 é concentração-dependente. Raras alterações morfológicas celulares e nucleares, com poucas células em apoptose foram observadas em HepG2 na presença de fisetina. Concluindo, embora vários outros testes de citotoxicidade e mecanismo de ação devam ser realizados para a introdução de fisetina como um novo fármaco, os resultados apresentados mostram um perfil favorável para conduzir ao estudo e desenvolvimento desta substância no tratamento de criptococose e dermatofitose.

Les bactéries Gram-négatif possèdent une structure d'enveloppe, ainsi que des pompes d'efflux (i.e., systèmes de transport actif permettant de détoxifier la cellule bactérienne) qui les rendent naturellement résistantes aux antibiotiques. Ces deux caractéristiques constituent de véritables barrières qui s'opposent à l'accumulation d'une grande variété d'antibiotiques près de leur cible, à l'intérieur de la bactérie. La perturbation des mécanismes s’opposant à l’accumulation d’antibiotiques par des agents chimiosensibilisants représente une stratégie prometteuse.L’objectif de cette thèse était de mieux comprendre les mécanismes d'inhibition de la résistance qui s’oppose à l’accumulation d’antibiotiques chez les bactéries Gram- négatif.Dans un premier temps l'activité de divers agents chimiosensibilisants synthétiques a été caractérisée. Trois dérivés ont été identifiés pour augmenter significativement l'activité synergique avec les antibiotiques, préalablement observée avec le géraniol. Ces dérivés ont montré une activité inhibitrice des pompes d'efflux ou perméabilisatrice de la membrane externe, pouvant être à l'origine des synergies observées.Dans un second temps, une méthode de criblage a été mise au point, en permettant la détection spécifique des agents chimiosensibilisants tout en décrivant leur mécanisme d'action.Ces travaux de thèse ont participé à proposer une solution thérapeutique brevetée au stade pré-clinique. Ils ont en outre permis de mettre en place des outils originaux pour identifier de nouveaux chimiosensibilisants, mais aussi pour mieux comprendre comment perturber les barrières s'opposant à l'accumulation d'antibiotiques. / Gram-negative bacteria are naturally resistant to many classes of antibiotics thanks to their ability to control the accumulation of drugs. Decreasing membrane barrier permeability and producing efflux pumps that expel drugs outside bacteria, represent the prevalent mechanisms of this resistance. One of the most promising solutions consists in restoring antibiotic activity by targeting such barriers to accumulation, with chemosensitizers.The purpose of my PhD was to better understand the inhibition of resistance that opposes the accumulation of antibiotics in Gram-negative bacteria.In the first stage of the study, the activity of various synthetic chemosensitizers has been characterized. Three compounds were identified to significantly increase the synergistic activity with antibiotics, that was previously observed with geraniol. These derivatives showed an efflux pump inhibition or an outer membrane permeabilization effect, that could be related to the observed synergy.In the second stage of the study, a screening method has been developed for the specific detection of chemosensitizers, while describing their mechanism of action.This work participated in proposing a patented therapeutic solution in the preclinical stage. This study has led to new tools to identify novel chemosensitizers, but also to better understand how to impair the barriers opposing the accumulation of antibiotics.

Malaria is a parasitic disease that is caused by the plasmodium parasite. Plasmodium infection has affected man for thousands of years. With advances in drug discovery over the past century, malaria has evolved to possess resistance to most mainline therapeutics. This war of drug discovery vs plasmodium evolution continues to be fought to this very day, with attempts to eradicate malaria worldwide. Frontline treatments such as chloroquine, artemisinin, and atovaquone/proguanil have all seen parasitic resistance in strains of P. vivax as well as P. falciparum. While plasmodium possesses resistance to most classes of anti-malarials, the 8-aminoquinoline (8-AQ) class has seen minimal resistance development. 8-AQs have been shown to be effective against erythrocytic and exo-erythrocytic forms of plasmodium, and are often given in combination with a blood schizonticide such as chloroquine or artemisinin. These combinations clear all forms of plasmodium infection. With 8-AQs unique set of anti-malarial properties and the advent of increased drug resistance to other drugs, much research is being done to understand 8-AQs mechanism of action and toxicity. 8-AQ use is limited due to inducing extreme hemolytic anemia in those with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Primaquine is the only 8-AQ molecule available on the market with tafenoquine, an analog primaquine, currently in phase III clinical trials. It is believed that if the mechanism of action and toxicity of the 8-AQs are understood, then we can create new generation anti-malarials that will maintain the unique action of 8-AQs while reducing their toxicity. Studies have shown that 8-AQ mechanism of action has been attributed to the generation of unstable metabolites that induce ROS production in the parasite, as well as mitochondrial swelling. While there is some evidence suggesting molecular targets of 8-AQs, the actual target is still unknown. When 8-AQs is given in combination with chloroquine, a synergistic effect is observed. While chloroquine has no activity against liver stages, it still somehow potentiates primaquine’s activity in those stages. This mechanism of synergy in liver stages is not well understood, and its understanding can give us increased understanding of basic plasmodium biology in the liver. Additionally, more information about the mechanisms of action of both chloroquine and primaquine could be elucidated. Tagging drugs with fluorescent probes is a technique that can give much information about the drug’s pharmacological activity in vitro, and sometimes in vivo as well. Such an approach has been used for various disease states such as HIV and cancer. Malaria is no exception; fluorescent probes of artemisinin and chloroquine have been used to examine resistance mechanisms to both molecules. In addition to 8-AQs, there are other older antimalarials that have received attention recently due to increases in resistance. Menoctone, a hydroxynapthoquinone that subsequently lead to the discovery of atovaquone, has recently gained increased attention because of its similarities to atovaquone. Research surrounding menoctone was abandoned due to the discovery of more efficacious compounds. Similar to 8-AQs, understanding the mechanisms of action and resistance to menoctone could give us much more information about plasmodium responses to this class of compounds. This understanding could potentially lead to the discovery of novel therapeutics. To understand mechanisms of action and synergy of 8-AQs, we report the creation of novel fluorescent probes of the 8-AQ molecules primaquine and tafenoquine. The organic synthesis was designed and characterization was confirmed by NMR and high resolution mass spectra, and the fluorescent properties were examined using absorbance and steady-state emission experiments. We found that the anti-malarial, anti-leishmaniasis, and cytotoxic properties of these novel probes were similar to the parent compounds. These probes localized in the cytoplasm of infected parasites in vitro. We also attempted to view their localization in liver stage infection, and investigated the synergistic combination of 8-AQs with chloroquine and quinine. Menoctone resistance was induced in vivo to determine mechanisms of resistance. Cross resistance to atovaquone was observed, and the mutation responsible for resistance was also found.

Les imidazoquinoxalines (imiqualines), molécules bioactives originales analogues chimiques de l’imiquimod et présentant un important potentiel anticancéreux, ont été explorées afin d’élucider leurs mécanismes d'action. Les molécules EAPB0203 et EAPB0503, identifiées lors d’études antérieures comme étant les « têtes de séries », ont montré un effet cytotoxique puissant in vitro sur des lignées cellulaires cancéreuses humaines de mélanome et de lymphomes T. Nous avons étudié l’effet cytotoxique de 13 imiqualines nouvellement synthétisées sur une lignée cellulaire de mélanome humain (A375). Tous les composés ont montré un effet cytotoxique important. L’effet cytotoxique a été démontré sur d’autres lignées cellulaires cancéreuses humaines (côlon, sein et lymphome T de l’adulte).Un blocage du cycle cellulaire en phase G2/M a été mis en évidence par cytométrie en flux sur des cellules A375 traitées par EAPB0203 et EAPB0503. Cet arrêt du cycle cellulaire semble être en relation avec un effet inhibiteur de la polymérisation de la tubuline. En effet, nos résultats ont montré que l’EAPB0503 et 3 autres imiqualines inhibent la polymérisation de la tubuline. L’étude de modélisation moléculaire de la liaison à de la tubuline a montré que ces composés se fixent sur le site de la colchicine.Une analyse transcriptomique sur EAPB0503 a été effectuée pour élucider le mécanisme d'action des imiqualines. Cette étude a été faite sur la lignée A375 en comparaison avec 13 anticancéreux de référence. L’étude transcriptomique a montré que EAPB0503 a une composante antitubuline tout en révélant un mécanisme d’action original. Deux hypothèses mécanistiques pour EAPB0503 ont ainsi été identifiées : 1/ altération de la voie de signalisation liée aux intégrines, 2/ altération de la voie de signalisation du récepteur TNFR et de FasL.Des analyses fonctionnelles in vitro nous ont permis d’explorer ces hypothèses. Ainsi, une altération uniquement des voies de signalisation PI3K/AKT et RAS/MAPK, toutes deux liées aux intégrines, a été observée. La première hypothèse semble donc validée. De plus, ce résultat a été confirmé par l’étude de l’expression et de la phosphorylation de ERK.Finalement, nous avons développé une formulation injectable par voie intraveineuse de EAPB0503 à base de nanocapsules. Cette formulation a d’abord été testée in vitro et in vivo sur un modèle de lymphome. Ces études ont pu mettre en évidence l’absence de toxicité des nanoparticules vides et le maintien de l’activité cytotoxique de EAPB0503 encapsulé in vitro, avec un effet immunomodulateur in vivo qui demande à être exploré. / The imidazoquinoxalines (imiqualines), original bioactive molecules and chemical analogues of imiquimod and with significant anti-cancer potential, were explored in order to elucidate their mechanisms of action. The molecules EAPB0203 and EAPB0503 identified in previous studies as leader, showed potent in vitro cytotoxic effect on human cancer cell lines of melanoma and T lymphoma. We studied the cytotoxic effect 13 newly synthesized imiqualines on a cell line of human melanoma (A375). All compounds showed a significant cytotoxic effect. The cytotoxic effect was shown on other human cancer cell lines (colon, breast and adult T lymphoma).A cell cycle block in G2 / M phase was demonstrated by flow cytometry on A375 cells treated with EAPB0203 and EAPB0503. This cell cycle arrest seems to be related with an inhibitory effect on the polymerization of tubulin. Indeed, our results showed that EAPB0503 and three other imiqualines inhibit tubulin polymerization. The molecular modeling study of binding to tubulin showed that these compounds bind at the colchicine site.A transcriptomic analysis on EAPB0503 was performed to elucidate the mechanism of action of imiqualines. This study was made on the A375 line compared with 13 approuved anticancer molecules. This transcriptomic study showed that EAPB0503 has an antitubulin effect while revealing a novel mechanism of action. Two mechanistic hypotheses for EAPB0503 were identified: 1/ alteration of the signaling pathway linked to integrin, 2/ alteration of the signaling pathway TNFR receptor and FasL.In vitro functional analyses have allowed us to explore these hypotheses. Thus, alteration only PI3K / AKT and RAS / MAPK signaling pathways, both related to integrins, was observed. The first hypothesis seems confirmed. Moreover, this result was confirmed by the study of the expression and phosphorylation of ERK.Finally, we developed an intravenously injectable formulation of EAPB0503 based on nanocapsules. This formulation was first tested in vitro and in vivo on lymphoma model. These studies could highlight the lack of toxicity of empty nanoparticles and retention of the cytotoxic activity of encapsulated EAPB0503 in vitro, with an in vivo immunomodulatory effect which needs to be explored.

O aumento na incidência de infecções fúngicas e a alta toxicidade ou elevado índice de resistência associado aos antimicóticos comerciais, criou um mercado carente de novas drogas. Neste contexto, os peptídeos antimicrobianos (AMPs) surgem como uma alternativa promissora ou fonte de conhecimento por desempenhar ação inibidora de crescimento e/ ou letal contra bactérias Gram-positivas e Gram-negativas, fungos, parasitas e/ ou vírus, além de atividade antitumoral e efeito imunomodulador. Como os mecanismos pelos quais eles o fazem são diferentes daqueles das drogas não peptídicas, os AMPs estão pouco associados ao desenvolvimento de resistência microbiana. A hemoglobina (Hb) é uma fonte de peptídeos com funções biológicas diversas. O fragmento 33-61 (Hb33-61) da cadeia &#945; da Hb bovina foi o primeiro AMP descrito a ser gerado in vivo no trato gastrointestinal do carrapato Boophilus microplus. Nossos estudos posteriores usando CD e H1-RMN revelaram que a amidação C-terminal deste fragmento o tornava ainda mais ativo que o primeiro e que em presença de micelas de SDS o Hb33-61a apresenta uma dobra &#946; na porção N-terminal (Lys40-Phe43) e outra (Ser49- Ser52) seguida de &#945;-hélice no C-terminal (Ala53-Ala60), bem como um segmento Pro44-Leu48 capaz de mover-se independentemente e agir como uma dobradiça. Nossas investigações usando análogos sintéticos truncados do Hb33-61a mostraram que o Hb40-61a poderia ser sua porção mínima ativa por apresentar comportamento conformacional idêntico. Nossos estudos subsequentes enfocando as suas propriedades evidenciaram a sua capacidade de causar morte rápida de cepas de Candida, incluindo C. albicans resistentes ao fluconazol e extravasamento de conteúdo e formação de poros em LUVs, revelando sua ação permeabilizante de membrana. Em continuidade ao estudo do Hb40-61a, investigamos no presente trabalho as suas propriedades e o seu mecanismo de ação contra C. albicans. Para isso, sintetizamos, purificamos e caracterizamos esta hemocidina, o seu análogo inteiro composto por D aminoácidos (ent-Hb40-61a) e o seu análogo marcado com 5 (6) carboxifluoresceína (FAM-Hb40-61a). Ensaios com eritrócitos humanos confirmaram a baixa atividade hemolítica desses AMPs em meio de alta e baixa força iônica. O análogo ent-Hb40-61a apresentou a mesma atividade antifúngica que o análogo L, evidenciando um mecanismo de ação não-estereoespecífico. Análises de células de Candida tratadas com FAM-Hb40-61a por microscopia confocal mostraram que em ½ MIC e MIC o peptídeo deposita-se na membrana plasmática e é internalizado, respectivamente. Citometria de fluxo demonstrou que na MIC cerca de 97% das células encontram-se marcadas pelo peptídeo, confirmou a influência negativa da alta força iônica em sua atividade, mostrou que a internalização celular na MIC é independente da temperatura e que a alteração no metabolismo energético da célula afeta de maneira negativa a internalização do peptídeo. Ensaios de permeabilidade celular com Syto 09 e iodeto de propídeo confirmaram danos progressivos à membrana plasmática de C. albicans com o aumento da concentração do Hb40-61a. Experimentos usando DiBAC4(5) e de DPH revelaram que o Hb40-61a altera o potencial de membrana e afeta sua fluidez, respectivamente. Imagens preliminares das células tratadas e não tratadas com Hb40-61a por microscopia de força atômica (AFM) sugeriram alterações nas células de C. albicans após tratamento com a hemocidina. Medidas preliminares do diâmetro médio das células de C. albicans revelaram que elas diminuem após o tratamento com o peptídeo, o que pode ser mais um indício de dano à membrana plasmática por formação de poros e extravasamento de conteúdo intracelular. Assim, obtivemos fortes indícios de que o alvo do Hb40-61a é, de fato, a membrana plasmática das células de Candida, de que ele apresenta potencial de uso tópico para tratamento de candidíase e pode servir como modelo para o desenho de novas drogas antimicrobianas, peptídicas ou não, com propriedades ainda mais valiosas e índices terapêuticos mais elevados. Testes preliminares mostraram que é possível a adsorção do Hb40-58a à nanopartículas de PSS e que, em relação ao peptídeo livre, este arranjo mantém a atividade antifúngica com MIC superior e apresenta menor atividade hemolítica. / The increased incidence of fungal infections and the high toxicity or high level of resistance associated with conventional antimycotics created a demand for new drugs. Antimicrobial peptides (AMPs) constitute a promising alternative and/or an important source of knowledge due to their growth inhibitory action and/or lethality against Gram-positive and Gram-negative bacteria, fungi, parasites and/or viruses. Besides, AMPs display antitumoral and immunomodulator effects. As their mechanisms of action are different from those of non-peptide drugs, AMPs are less associated with the development of antimicrobial resistance. Hemoglobin (Hb) is a source of peptides with diverse biological functions. The fragment 33-61 (Hb33-61) of bovine Hb &#945; chain was the first AMP reported to be generated in vivo in gastrointestinal tract of Boophilus microplus. Our studies of Hb33-61 using CD and H1-NMR showed that amidation of its C-terminal (Hb33-61a) increases its activity; in the presence of SDS micelles, Hb33-61a is characterized by a central hinge joining the C-terminal region (containing a &#946; turn followed by a helical element) to the N-terminal region (that presents only a &#946; turn). Our previous investigations using synthetic truncated analogues of Hb33-61a suggested that Hb40-61a could be its minimal active portion as it presented equal biological and structural properties. Our subsequent studies focusing on its properties showed its ability to quickly kill Candida albicans strains (including those resistant to fluconazole) and to cause leakage of the contents of LUVs and pore formation in GUVs, revealing its membrane permeabilizing action. We further investigated the properties of Hb40-61a and its possible mechanism of action against C. albicans. To do it, we synthesized, purified and chemically characterized it, its all-D analogue (ent-Hb40-61a) and its analogue labeled with 5 (6) carboxyfluorescein (FAM-Hb40-61a). Tests using human erythrocytes confirmed the low toxicity of these hemocidins at high or low ionic strength. The ent-analogue was as active as the all-L compound suggesting a non stereospecific mechanism of action. Confocal microscopy analysis of Candida cells treated with FAM-Hb40-61a showed that at ½ MIC and MIC, the peptide deposits on the plasma membrane and is internalized, respectively. Flow cytometry results showed that at the MIC about 97% of the cells are marked by the peptide, confirmed the negative influence of high ionic strength on its antifungal activity and showed that the cellular internalization at the MIC is partially dependent on ATP, but independent on the temperature. Cell permeabilization assays using Syto 09 and propidium iodide confirmed progressive damage of the membrane as a function of Hb40-61a concentration. Experiments employing DiBAC4 (5) and DPH revealed that the Hb40- 61a alters the membrane potential and affects its fluidity, respectively. Preliminary atomic force microscopy (AFM) images of C. albicans cells before and after treatment with Hb40-61a suggested morphological changes in the plasma membrane. Preliminary measurements of the average diameters of the fungal cells indicated size reduction after treatment with the Hb40-61a probably resulting from pore formation and leakage of cell contents. Thus, we obtained strong evidences that the target of this peptide is indeed the plasma membrane of Candida cells. Thus, this hemocidin have the potential to be used topically for treating candidiasis and/or serve as model for the design of new antimicrobial drugs, peptide or non-peptide, with even more valuable properties and improved therapeutic indexes. Preliminary tests confirmed the possibility of adsorbing Hb40-58a to nanoparticles of polystyrene sulfate (PSS) and that resulting assembly is still active and less hemolytic than the free peptide.

A primary challenge in the analysis of high-throughput biological data is the abundance of correlated variables. A small change to a gene's expression or a protein's binding availability can cause significant downstream effects. The existence of such chain reactions presents challenges in numerous areas of analysis. By leveraging knowledge of the network interactions that underlie this type of data, we can often enable better understanding of biological phenomena. This dissertation will examine network-based statistical approaches to the problems of mechanism-of-action inference, characterization of gene expression changes, and prediction of drug response. First, we develop a method for multi-target perturbation detection in multi-omics biological data. We estimate a joint Gaussian graphical model across multiple data types using penalized regression, and filter for network effects. Next, we apply a set of likelihood ratio tests to identify the most likely site of the original perturbation. We also present a conditional testing procedure to allow for detection of secondary perturbations. Second, we address the problem of characterization of cellular phenotypes via Bayesian regression in the Gene Ontology (GO). In our model, we use the structure of the GO to assign changes in gene expression to functional groups, and to model the covariance between these groups. In addition to describing changes in expression, we use these functional activity estimates to predict the expression of unobserved genes. We further determine when such predictions are likely to be inaccurate by identifying GO terms with poor agreement to gene-level estimates. In a case study, we identify GO terms relevant to changes in the growth rate of S. cerevisiae. Lastly, we consider the prediction of drug sensitivity in cancer cell lines based on pathway-level activity estimates from ASSIGN, a Bayesian factor analysis model. We use penalized regression to predict response to various cancer treatments based on cancer subtype, pathway activity, and 2-way interactions thereof. We also present network representations of these interaction models and examine common patterns in their structure across treatments.